Live Breaking News & Updates on Eric Schuur

Stay updated with breaking news from Eric schuur. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Mazen Noureddin, MD, MHSc joins HepaTx's Scientific Advisory Board

/PRNewswire/ HepaTx, a preclinical-stage biotechnology company developing cell therapies for liver diseases, announced today that Mazen Noureddin, MD, MHSc,. ....

United States , Jc Walter Jr , Eric Schuur , Mazen Noureddin , Prnewswire Hepatx , Davidm Underwood Center , Sinai Medical Center , Houston Research Institute , Fatty Liver Program At Cedars , Center Sherrie Alan Conover , Scientific Advisory , Fatty Liver Program , Cedars Sinai Medical , Transplant Center Sherrie , Alan Conover Center , Liver Disease , Houston Methodist Hospital , Scientific Advisory Board ,

HepaTx appoints Salah Kivlighn as new CEO

HepaTx appoints Salah Kivlighn as new CEO
News provided by
Share this article
Share this article
PALO ALTO, Calif., April 15, 2021 /PRNewswire/ HepaTx Corporation, a preclinical stage company developing cell therapies for the treatment of liver disease, is pleased to announce the appointment of Salah Kivlighn, PhD as Chief Executive Office. An experienced business leader, Dr. Kivlighn will succeed Co-founder Eric Schuur, PhD and assume responsibilities on April 15
th, 2021.
Dr. Kivlighn brings a rare blend of science and business acumen to HepaTx. His experience spans therapeutic classes including oncology, vaccines, immuno-oncology, and cardiovascular disease treatments and multiple aspects of drug development and commercialization. His accomplishments include: guided the discovery, evolution, and commercialization of Losartan (Cozaar®), a market-leading antihypertensive drug becoming a $3.5B franchise (Merck & Co.); co-led the development and commerc ....

Eric Schuur , Salah Kivlighn , Losartan Cozaar , Arthur Guyton , Medimmune Astrazeneca , States Pharmacopeia , Kite Pharmaceuticals , Merck Co , Hepatx Corporation , University Of Houston , Chief Executive , Co Founder Eric Schuur , Recently Salah , United States Pharmacopeia , Commercial Vice President , Chief Executive Officer Award , Prix Galien Award , New Biotechnology , ஆர்தர் பையன் , மாநிலங்களில் மருந்தகம் , காத்தாடி மருந்துகள் , மெர்க் இணை , பல்கலைக்கழகம் ஆஃப் ஹூஸ்டன் , தலைமை நிர்வாகி , ஒன்றுபட்டது மாநிலங்களில் மருந்தகம் , வணிகரீதியானது துணை ப்ரெஸிடெஂட் ,

HepaTx, Namocell, and Takara Bio USA complete second phase of collaboration on single cell analysis for cell therapy to treat late-stage liver diseases

Share this article
Share this article
PALO ALTO, Calif., March 12, 2021 /PRNewswire/ HepaTx Corporation, Namocell Inc., and Takara Bio USA, Inc. (TBUSA) announced successful completion of the second phase of their collaboration on single cell analysis of hepatocyte-like cells (iHeps) differentiated from adipose tissue-derived stromal cells (ASCs) using Namocell s Single Cell Dispensers and Takara Bio s SMART-seq® kits to characterize HepaTx s novel cell therapies for liver disease. The results of the second phase demonstrated a 95% success rate in single cell isolation and library construction. Single cell RNA-seq showed distinct clusters of cells at various differentiation stages. The high reproducibility of results within sample groups will support development of novel cell therapies and validate production processes. ....

Takara Bio , Suvarna Gandlur , Eric Schuur , Jun Yu Lin , Namocell Inc , Takara Bio Inc , Takara Bio United States Inc , Prnewswire Hepatx Corporation , Takara Bio United States , Single Cell Dispensers , Single Cell Dispenser , Associate Director , Next Generation Sequencing , Takara Bio United , Bio United States , தகர உயிர் , தகர உயிர் இன்க் , தகர உயிர் ஒன்றுபட்டது மாநிலங்களில் இன்க் , தகர உயிர் ஒன்றுபட்டது மாநிலங்களில் , ஒற்றை செல் விநியோகிப்பாளர்கள் , ஒற்றை செல் விநியோகிப்பாளர் , இணை இயக்குனர் , அடுத்தது ஜெநரேஶந் வரிசைப்படுத்துதல் , தகர உயிர் ஒன்றுபட்டது , உயிர் ஒன்றுபட்டது மாநிலங்களில் ,